NCT03993288 - Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia. | Biotech Hunter

Enrollment

267

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions

Mild and Moderate Iron-deficiency Anaemia

Interventions

DRUG

Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)

Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks

DRUG

MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)

Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks

Trial Locations (18)

Sandoz Investigative Site, Moscow

Sandoz Investigative Site, Krasnogorsk